SUPN logo

Supernus Inc. (SUPN)

$29.04

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on SUPN

Market cap

$6.03B

EPS

-0.7

P/E ratio

--

Price to sales

3.56

Dividend yield

--

Beta

1.214522

Price on SUPN

Previous close

$28.83

Today's open

$28.72

Day's range

$28.45 - $29.69

52 week range

$25.92 - $42.81

Profile about SUPN

CEO

Jack A. Khattar

Employees

838

Headquarters

Rockville, MD

Exchange

Nasdaq Global Select

Shares outstanding

207724098

Issue type

Common Stock

SUPN industries and sectors

Healthcare

Pharmaceuticals

News on SUPN

Supernus, Inc. to Participate in the 2026 Jefferies Global Healthcare Conference in London

ROCKVILLE, Md., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that Jack A.

news source

GlobeNewsWire • Nov 10, 2026

news preview

This Supernus Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

news source

Benzinga • Nov 9, 2026

news preview

Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

news source

GlobeNewsWire • Nov 2, 2026

news preview

Supernus Pharmaceuticals Q3 Earnings Call Highlights

Supernus Pharmaceuticals NASDAQ: SUPN reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov. 2 following shareholder approvals.

news source

MarketBeat • Oct 29, 2026

news preview

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Oct 30, 2026

news preview

Supernus Announces Third Quarter 2026 Financial Results

ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2026 and associated Company developments.

news source

GlobeNewsWire • Oct 29, 2026

news preview

Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.01 per share a year ago.

news source

Zacks Investment Research • Oct 30, 2026

news preview

Earnings Preview: Supernus Pharmaceuticals (SUPN) Q3 Earnings Expected to Decline

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 22, 2026

news preview

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

news source

GlobeNewsWire • Oct 21, 2026

news preview

Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026

ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026.

news source

GlobeNewsWire • Oct 19, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Supernus Inc.

Open an M1 investment account to buy and sell Supernus Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in SUPN on M1